with early diabetic nephropathy
10.3760/cma.j.issn.1673-4246.2016.10.006
- VernacularTitle:渴络欣胶囊配合厄贝沙坦片治疗早期糖尿病肾病临床研究
- Author:
Xuedan ZHANG
- Publication Type:Journal Article
- Keywords:
Diabetic nephropathies;
Early medical intervention;
Keluoxin capsule;
Integrated Chinese traditional and western medicine therapy
- From:
International Journal of Traditional Chinese Medicine
2016;38(10):884-887
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the clinical effect and safety evaluation of Keluoxin capsule in the treatment of the patients with early diabetic nephropathy. Methods One hundred and forty-nine patients with early diabetic nephropathy were randomly divided into the treatment group and control group, 74 in each group. The control group was treated with Keluoxin placebo capsules (2 g every time, 2 times a day, oral) and Irbesartan (150 mg every time, once a day, oral) simultaneously; and thetreatment group was treated with Keluoxin capsules (2 g every time, 2 times a day, oral) and Irbesartan (150 mg every time, once a day, oral) simultaneously. Both groups were treated for 24 weeks. The clinical curative effect, the changes of blood sugar levels, TG, TC, LDL-C, HDL-C, BUN, Scr, 24 hUTP and 24 hUAE were assessed and compared, and the treatment safety of Keluoxin capsule was assessed. Results Compared with the control group, the markedly effective rate and total effective rate of treatment group increased significantly (χ2=9.208, P<0.05). The levels of blood sugar (7.4 ± 0.6 mmol/L vs. 6.2 ± 0.5 mmol/L, P<0.05), TC (7.1 ± 2.3 mmol/L vs. 5.4 ± 1.6 mmol/L, P<0.05), TG (2.7 ± 0.8 mmol/L vs. 2.3 ± 0.5 mmol/L, P<0.05), LDL-C (4.2 ± 1.6 mmol/L vs. 3.5 ± 1.2 mmol/L, P<0.05), BUN (11.4 ± 3.3 mmol/L vs. 6.4 ± 2.5 mmol/L, P<0.05), SCr (158.7 ± 29.5μmol/L vs. 116.2 ± 23.1μmol/L, P<0.05), 24 hUTP (237.1 ± 46.3 mg vs. 201.4 ± 38.2 mg, P<0.05) and 24 hUAE (157.3 ± 40.8 mg vs. 109.4 ± 28.5 mg , P<0.05) in the treatment group were significantly lower than those in the control group;but the level of HDL-C showed no significantly difference between two groups (1.1 ± 0.4 mmol/L vs. 1.3 ± 0.6 mmol/L, P>0.05). There was no adverse event between two groups. Conclusions The clinical effect of Keluoxin capsule can benefit the patients with early diabetic nephropathy.
